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ABSTRACT
Introduction: With the increasing use of
intravitreal administration of corticosteroids in
macular edema, steroid-induced intraocular
pressure (IOP) rise is becoming an emergent
issue. However, for patients in whom
intravitreal steroids are indicated, there are no
specific recommendations for IOP monitoring
and management after intravitreal
administration of corticosteroids.
Method: An expert panel of European
ophthalmologists reviewed evidence on
corticosteroid-induced IOP elevation. The
objective of the panel was to propose an
algorithm based on available literature and
their own experience for the monitoring and
management of corticosteroid-induced IOP
elevation, with a focus on diabetic patients.
Results: Data from trials including diabetic
patients with a rise of IOP after intravitreal
steroid administration indicate that
IOP-lowering medical treatment is sufficient
for a large majority of patients; only a small
percentage underwent laser trabeculoplasty or
filtering filtration surgery. A 2-step algorithm is
proposed that is based on the basal value of IOP
and evidence for glaucoma. The first step is a
risk stratification before treatment. Patients
Enhanced content To view enhanced content for this
article go to http://www.medengine.com/Redeem/45C4
F0604DE73D4B.
F. J. Gon˜i (&)
Glaucoma Consultant, CTIG-Hospital Quiro´n
Teknon, Barcelona, Spain
e-mail: francisgoni@yahoo.com
I. Stalmans
Department of Ophthalmology, University
Hospitals Leuven, Louvain, Belgium
P. Denis
Department of Ophthalmology, Hoˆpital de la
Croix-Rousse, Lyon, France
J.-P. Nordmann
University Paris Descartes, Quinze-Vingts Hospital,
Paris, France
S. Taylor
University of Surrey and Royal Surrey County
Hospital, Surrey, UK
M. Diestelhorst
Zentrum fu¨r Augenheilkunde, Universita¨t zu Ko¨ln,
Cologne, Germany
A. R. Figueiredo
University of Lisbon, Oftalmolaser Clinic, Lisbon,
Portugal
D. F. Garway-Heath
NIHR Biomedical Research Centre, Moorfields Eye
Hospital and UCL Institute of Ophthalmology,
London, UK
Ophthalmol Ther (2016) 5:47–61
DOI 10.1007/s40123-016-0052-8
normotensive at baseline (IOP B 21 mmHg), do
not require additional baseline diagnostic tests.
However, patients with baseline ocular
hypertension (OHT) (IOP[21 mmHg) should
undergo baseline imaging and visual field
testing. The second step describes monitoring
and treatment after steroid administration.
During follow-up, patients developing OHT
should have baseline and periodical imaging
and visual field testing; IOP-lowering treatment
is proposed only if IOP is [25 mmHg or if
diagnostic tests suggest developing glaucoma.
Conclusion: The management and follow-up of
OHT following intravitreal corticosteroid
injection is similar to that of primary OHT. If
OHT develops, IOP is controlled in a large
proportion of patients with standard IOP
treatments. The present algorithm was
developed to assist ophthalmologists with
guiding principles in the management of
corticosteroid-induced IOP elevation.
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INTRODUCTION
Diabetic macular edema (DME) is a common
complication of diabetes involving the
microvasculature of retina. DME is the
consequence of a breakdown in the
blood-retina barrier which leads to retinal
thickening resulting from the accumulation of
fluid and exudates [1]. DME is the primary
reason of vision loss in diabetic retinopathy,
which is a leading cause of blindness in
countries with a developed economy [2, 3].
The goal of therapy in DME is to preserve
retinal function by reducing vascular leakage
causing edema (expressed as retinal thickening).
Laser photocoagulation and intravitreal
administration of anti-vascular endothelial
growth factor (anti-VEGF), as first line therapy,
or corticosteroids, as second line therapy, have
demonstrated efficacy [1]. In contrast with
anti-VEGFs, which inhibit only the effect of
VEGF, corticosteroids have multiple
mechanisms of action on various pathways of
the inflammatory cascade thus, reducing the
effects of VEGF, inflammatory cytokines and
other mechanisms involved in the pathogenesis
of DME [1].
With the increasing use of corticosteroids,
steroid-induced elevated intraocular pressure
(IOP) or ocular hypertension (OHT) are
becoming an emergent problem with the
reports of incidence ranging from 11% to 79%
[4]. The risk of IOP elevation depends on the
dose and chemical structure of the steroid,
duration of therapy and route of
administration [5]. The variable risk according
to the route of administration has motivated
some authors to evaluate a provocation test
before an intravitreal injection. Risk factors for a
steroid-induced rise in IOP have been identified:
primary open-angle glaucoma (POAG), family
history of glaucoma, diabetes, myopia,
rheumatoid arthritis, old age or age less than
6 years [5, 6]. However, there are no specific
recommendations regarding patient selection
and monitoring following intravitreal use of
corticosteroids in the setting of diabetic
retinopathy. The guidelines of the European
Glaucoma Society (EGS) provide
recommendations for the management of
glaucoma due to corticosteroid treatment, but
the common situation of diabetic patients with
macular edema being treated with intravitreal
corticosteroids is not specifically addressed [5].
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The objective of this article was to review
current evidence on steroid-induced IOP
elevation and OHT and to provide guidance
for the monitoring and management of IOP
following treatments with corticosteroids in
DME.
METHODS
The authors of this article are an expert panel of
European ophthalmologists who met in Paris in
March 2015. The panel’s intention was first to
review evidence on corticosteroid-induced IOP
elevation in DME patients. Since data are sparse
or incomplete regarding the specific use of
corticosteroids in DME, the panel also
considered the relationship between OHT and
onset of glaucoma, mechanisms of
corticosteroid-induced IOP elevation and
current guidelines for the management of
corticosteroid-induced IOP elevation.
A monitoring and management algorithm
has been proposed that was designed to be
acceptable for use across Europe and that can be
adapted in local countries. The proposed
algorithm is evidence based as far as possible.
When necessary, the recommendations were
based on panel’s experience.
This article is intended to be a practical tool for
ophthalmologists in the management of
corticosteroid-induced IOP elevation. This
article is based on previously conducted studies,
and does not involve any new studies of human or
animal subjects performed by any of the authors.
RESULTS
Intravitreal Corticosteroids Used in DME
The direct injection of corticosteroid into the
vitreous allows the administration of a large
bolus of drug. The therapeutic level is rapidly
achieved and the drug is administered in the
vicinity of the target tissue. Moreover, systemic
absorption and systemic side effects are
minimized. The most common corticosteroids
used for intravitreal administration are
triamcinolone acetonide, fluocinolone
acetonide and dexamethasone.
Triamcinolone acetonide is minimally water
soluble and is administered as a suspension.
Most frequently the 4 mg dose is used and its
duration of action is approximately 3 months
[7]. Compared with triamcinolone,
dexamethasone is more potent with a shorter
duration of action [8]. The intravitreal
administration of dexamethasone has been
studied at 0.4 and 0.8 mg. Due to its short
duration of action, a single injection is not
sufficient to achieve a sustained therapeutic
effect in DME which is a chronic disease [9].
Repeated intravitreal administration of
corticosteroids for maintaining therapeutic
effects increases the risk of adverse events,
such as endophthalmitis or vitreous
haemorrhage [7, 10]. Sustained-release
implants have, therefore, been developed to
reduce injection frequency and reduce the risk
of such complications [11]. These implants are
either biodegradable or non-biodegradable.
With non-biodegradable implants, the release
of the corticosteroid is more precise with a
longer therapeutic effect [4].
Retisert (Bausch and Lomb, Inc., Rochester,
NY, USA) is a non-biodegradable implant that is
inserted via the pars plana. It is sutured to the
sclera and fluocinolone acetonide is released for
30 months at a controlled rate [12]. This drug
has no license in Europe and will not be
discussed in this review.
ILUVIEN (Alimera Sciences, Inc, Alpharetta,
GA, USA) is a non-biodegradable implant
inserted into the vitreous cavity via the pars
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plana through a 25-gauge needle. Fluocinolone
acetonide is released at a rate of 0.2 lg per day
for up to 36 months [13].
Ozurdex (Allergan, Inc, Irvine, CA, USA) is a
biodegradable sustained-release device that is
inserted into the vitreous cavity using a stepped
incision through a 23-gauge needle. One
dexamethasone implant contains 700 lg of
dexamethasone which is released for up to
6 months [14].
Pharmacokinetics of Intravitreal
Corticosteroids
Steroids administered in the vitreous are
eliminated via two main pathways. The flow
of aqueous humor through the anterior
chamber angle is the first pathway and the
second is posteriorly through the blood-retinal
barrier [11, 15]. The concentration of the
intravitreal corticosteroids, and consequently
its duration of action, depends on the clearance
rate from the vitreous [16, 17].
Direct measurements of corticosteroid
concentrations in vitreous are difficult and
experimental animal models have been
developed: triamcinolone acetonide in rabbit
[18, 19], dexamethasone implants (Ozurdex) in
monkey [20], fluocinolone acetonide (ILUVIEN)
in rabbit [21]. Nevertheless, small series have
been performed in human for triamcinolone
acetonide [7], fluocinolone acetonide
(ILUVIEN) [22, 23]. No study has been
published for dexamethasone implants
(Ozurdex) in the human eye.
From these pharmacokinetic studies, the
duration of the therapeutic window has been
evaluated to be *1–3 months for triamcinolone
acetonide 4 mg, *2–4 months for Ozurdex
(700 lg of dexamethasone) and up to
36 months for ILUVIEN (0.2 lg/day of
fluocinolone acetonide) [24].
Evidence Base for Corticosteroid-Induced
Ocular Hypertension
Topical, intravitreal and high-dose and
long-term systemic corticosteroid therapy can
induce subacute or chronic elevation of IOP and
particularly in patients with POAG [25, 26].
Thus, IOP elevation has been observed in 40%
of normal subjects after 4–6 weeks of treatment
with topical 0.1% dexamethasone and 100% of
patients with POAG [4].
It has been suggested that POAG and
steroid-induced glaucoma share common
pathogenic mechanisms; OHT induced by
corticosteroids is similar to POAG since, in
both cases, the outflow facility is decreased
[27]. The ultrastructural basis of
corticosteroid-induced obstruction within the
trabecular meshwork remains poorly
understood. Some studies suggested that
extracellular matrix alterations contribute to
decreased outflow facility within the trabecular
meshwork or the juxtacanalicular connective
tissue [28]. The upregulation of the gene of
myocilin has been evidenced in cultured
trabecular meshwork cells [29]. Moreover,
mutations of this gene have been found to be
associated with POAG [30].
Whichever corticosteroid drug is
administered into the vitreous, the incidence
of OHT increases with the dose: 32.1% and
45.9% for triamcinolone 4 and 25 mg [4], 37.1%
and 45% for ILUVIEN 0.2 and 0.5 lg/day [31],
27% and 32% for Ozurdex 0.35 and 0.7 mg [32],
respectively. There is a correlation between the
steroid concentration in aqueous humor and
the increased risk of OHT in DME patients after
intravitreal administration of fluocinolone
acetonide [23]. The authors concluded that, in
susceptible patients, prolonged aqueous levels
of fluocinolone acetonide[1 ng/ml moderately
increases the risk of IOP rise and levels [6 ng/
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mL are associated with a markedly increased
risk. Compared to the control arm, significant
anatomical signs of development of glaucoma
were not detected in the ILUVIEN studies [33].
The time course of OHT after intravitreal
administration of corticosteroids varies
according to the molecule and dose. Moreover,
comparisons between studies are limited by the
various definitions used for the steroid induced
rise of IOP. In the systematic review of Kiddee
et al. the onset of OHT defined as IOP C21 or
C10 mmHg from baseline was 2–4 weeks in
randomized controlled trials and 1–8 weeks in
non-randomized studies after administration of
triamcinolone 4 mg [4]. However, in some
studies onset could be observed as early as
1 week or on the contrary 20–24 weeks after
administration. With the ILUVIEN 0.2 lg/day
implants, the onset of OHT began within
2–4 weeks with a maximum at 24–48 weeks
and a return to basal values 9–12 months after
implantation [22, 34, 35]. The time course of
OHT has not been reported with the
dexamethasone implant. Nevertheless, the
peak IOP occurred 60 days after implantation
and returned to basal values within 6 months
[36–39].
Although diabetes has been reported as a risk
factor of development of POAG after intravitreal
triamcinolone administration in a small
retrospective study (p = 0.050) [40], diabetes
was not considered a predictor of development
of POAG in both independent Ocular
Hypertension Treatment Study (OHTS)
(ClinicalTrials.gov identifier, NCT00000125)
and European Glaucoma Prevention Study [6,
7]. Elevated IOP [21 mmHg after
administration of 20 or 25 mg of
triamcinolone was statistically independent of
diabetes (p = 0.74 and p = 0.37, respectively)
[41, 42]. Another study with triamcinolone 4 or
8 mg did not find a relationship between an IOP
rise and diabetes [hazard ratio, 0.91; 95%
confidence interval (CI), 0.47–1.61, p = 0.760]
[43]. There is an increased risk of glaucoma in
patients with diabetes regardless of IOP level
[44], possibly explained by vascular
mechanisms, as diabetes causes microvascular
damage and may affect vascular autoregulation
of the retina and optic nerve.
Some authors hypothesized that side effects
related to corticosteroids may be explained in
part by the differences in drug lipophilicity and
partitioning into trabecular meshwork and lens
[45]. However, these results have been recently
rejected in the scientific literature [46].
Evidence Base for Elevated IOP After
Corticosteroids in DME
The effects on IOP of intravitreal administration
of corticosteroids during large trials for the
treatment of DME are summarized in Table 1.
The results of IOP elevation are, however,
difficult to compare since IOP was not a
primary endpoint and only reported as an
adverse event. Moreover, definitions of IOP
were not standardized with different cut-offs
for IOP elevation or OHT. Overall, the safety
results regarding elevated IOP in patients with
DME are similar to those reported in the
systematic review of Kiddee et al. which
included patients regardless of diabetes status
[4]. Nevertheless, a large proportion of patients
with DME received IOP-lowering medical
treatments and were largely well controlled
(Table 1). Some patients underwent laser
trabeculoplasty or incisional glaucoma surgery,
but the proportion was low, except for one
study of triamcinolone in which 9% underwent
glaucoma surgery [47].
Outcomes comparable to those seen in
controlled trials were obtained in recent
real-world studies [48–51]. The study of Lam
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et al. assessed the intravitreal dexamethasone
implant (Ozurdex) in 120 study eyes (including
34 eyes with diagnosis of DME) in patients
with C3 months of follow-up after the initial
dexamethasone implant [48]. An IOP rise
C?10 mmHg from baseline, C25 and
C35 mmHg were reported for 20.6%, 26.5%
and 2.9% of patients with DME. Glaucoma
surgery was performed for 1.7% of all patients
(no patient with DME had surgery). IOP
elevation in DME patients or patients with
retinal vein occlusion were comparable and
IOP-lowering medical treatment was
administered to 29.4% of patients with DME
and 16.7% of patients with retinal vein
occlusion.
The recent 1-year retrospective study of
Mazzarella et al. evaluated the effect of
intravitreal injection of dexamethasone
(Ozurdex) on IOP in 92 patients with macular
edema (including 36.5% with diabetic
retinopathy) either without OHT (group 1;
n = 65) or associated with glaucoma or OHT
(group 2; n = 27) [49]. After injection, OHT
([21 mmHg) was observed in 21.5% of eyes of
group 1 and 59.3% in group 2. In group 2, all
eyes required IOP-reducing treatment vs. 12.3%
in group 1. In general the rise of IOP was
transitory and only one patient required
filtration surgery. These results underscore the
need to monitor patients during corticosteroid
treatment, especially patients with a previous
history of OHT or glaucoma.
The 1-year prospective study of Massin et al.
evaluated the fluocinolone acetonide
intravitreal implant (ILUVIEN) in 16 patients
(17 eyes) with DME insufficiently responsive to
laser and anti-VEGF therapy. Patients with a
history of an IOP rise after intravitreal
corticosteroids were excluded. Elevation of IOP
was reported in three patients who were well
controlled by IOP-lowering eyedrops [50].
Overall, these studies indicate that diabetic
patients with intravitreal steroids have an
incidence of IOP increase and OHT
comparable with those of non-diabetic
patients. When necessary, IOP-lowering
medical treatment or laser trabeculoplasty is
sufficient for a large majority of patients and
glaucoma surgery is needed for only a small
proportion of patients.
Evidence Base for Onset of Glaucoma
Related to Ocular Hypertension
The OHTS was a multicenter, randomized,
prospective clinical trial designed to assess the
relationship between primary OHT and onset of
glaucoma. For this purpose, 1636 patients aged
from 40 to 80 years with high IOP were
randomized between IOP-lowering treatment
and no treatment [52]. The goal was to achieve
IOP\24 mmHg and an IOP decrease of at least
20% from baseline. The primary outcome was the
development of open-angle glaucoma (visual
field defects or optic disc deterioration). The
IOP was reduced by 22.5% in the treated group
and 4.4% in the no treatment group [53]. The
main results indicated that around 90% of
patients with OHT (baseline IOP between 24
and 32 mmHg) who are not treated had no
glaucoma after 5 years. IOP reduction by at least
20% was found to decrease the risk of conversion
from OHT to glaucoma by 50%. This large
randomized controlled study confirmed that
IOP reduction decreases the incidence of
glaucoma in patients with OHT [5]. The risk of
developing glaucoma as a result of a
corticosteroid-induced IOP rise may not be the
same as that for the development of primary
open-angle glaucoma in patients with OHT.
Hence, new studies are still needed to identify
the risk of developing glaucoma after treatment
with a steroid.
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Is A ‘Steroid Provocative Test’ Useful?
Few studies have directly addressed this point
i.e. initiating a short-acting steroid treatment to
assess a ‘steroid response’ on IOP before
initiating a sustained steroid release treatment.
However, previous studies on the effect of
topical corticosteroids on IOP are available.
Thus, pioneering studies in the 1960s showed
that topical corticosteroids caused elevated IOP
in a large proportion of patients [27, 54, 55].
These early studies showed that increased IOP is
observed in approximately one-third of people
after administration of topical corticosteroids
for several days (more than 90% in patients
with chronic glaucoma). Among ‘responders’,
the majority were low responders (IOP rise
\6 mmHg) and one-third were intermediate
responders (IOP rise from 6 to 15 mmHg) and
4–6% were high responders (IOP rise
[15 mmHg) [27, 54–56]. This IOP elevation
was usually transient, with a return to normal
within 2 weeks after discontinuation, provided
the treatment duration was short. Persistent IOP
elevations refractory to IOP-lowering treatment
were observed in 1–5% of cases [56].
More recently, Breusegem et al. investigated
the diagnostic value for a steroid response of a
topical dexamethasone provocative test before
intravitreal triamcinolone acetonide injection
[57]. The dexamethasone test had a sensitivity
of 25% (CI 95%, 0.07–0.52), a specificity of
100% (95% CI, 0.83–1.00), a positive predictive
value of 100% (95% CI, 0.40–1.00) and a
negative predictive value of 62% (95% CI,
0.44–0.79). It was thus concluded that a
positive response to topical dexamethasone is
a strong predictor of the response to intravitreal
triamcinolone acetonide; however, a negative
response does not guarantee there will be no
response to intravitreal triamcinolone
acetonide.
In the panel’s opinion, the benefit of a
corticosteroid provocation test is equivocal.
Since the great majority of steroid-induced
OHT can be managed with medical or laser
therapy, a positive steroid challenge does not
necessarily imply that a patient would not
benefit from intravitreal steroids; the clinician
and patient should consider the benefit-risk
balance before deciding on the best course of
action.
RECOMMENDATIONS
There is no evidence regarding the choice of
IOP-lowering treatment or the targeted IOP for
steroid-induced OHT in DME patients. The
guidelines of the EGS recommend: (1)
discontinuation of corticosteroid therapy or
switch to weaker steroid; (2) administration of
topical or systemic IOP-lowering medication;
(3) laser trabeculoplasty and (4) glaucoma
surgery in intractable cases [5]. These
recommendations are, however, not specific
for intravitreal administration, nor for patients
with DME. A systematic review by Kiddee
addressed the management of IOP but did not
discuss the specifics of the diabetic population
studied [4].
We propose two consecutive algorithms for
DME patients treated with intravitreal
corticosteroids—one for baseline risk
stratification (Fig. 1) and prior to
administering a corticosteroid and the second
is for the monitoring and management of IOP
after a corticosteroid has been administered
(Fig. 2). In the risk stratification algorithm,
patients with pre-existing or advanced
glaucoma are not eligible for treatment
according to respective package leaflets of
fluocinolone acetonide (ILUVIEN) and
dexamethasone (Ozurdex) implants [58, 59]
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(Fig. 1). Some authors have suggested that
pre-existing glaucoma should be a relative
contraindication for steroid use because
intravitreal steroids may be the only effective
treatment for some patients [6, 56]. The use of
intravitreal steroids in such patients would be
‘off-label’ as the products are not licensed for
use in these patients. For monitoring of patients
with IOP B21 mmHg, without a history of
IOP-lowering medication or IOP increase after
Patients without OHT Patients with OHT Glaucoma 
IOP < 21 mm Hg 
and 
No pre-existing IOP-lowering 
medication
and 
No history of previous steroid 
response 
IOP > 21 mm Hg 
or 
Patients controlled on IOP-
lowering medication(s) 
or 
History of steroid response 
with OHT 
IOP only* IOP + imaging of optic nerve 
head/RNFL + Visual field 
(Discuss with local glaucoma 
team according to local 
protocols. Omit visual field if 
likely to be non-contributory) 
Not licensed 
Specific wording according to 
package leaflets 
* If possible, combine imaging of optic nerve and fovea imaging to exclude normal-tension glaucoma
Fig. 1 Algorithm for the management of IOP elevation by retinal specialists: pre-injection considerations. IOP intraocular
pressure, OHT ocular hypertension, RNFL retinal nerve ﬁbre layer
Refer to glaucoma specialist
21< IOP < 25 mmHgIOP < 21 mmHg
Perform imaging + Visual Field
Consider TREATMENT at 1st or 
2nd visit (within1–2 weeks) with 
rise of IOP using medical 
(drops) or laser trabeculoplasty 
according to local agreement 
as for any ocular hypertension
REVIEW within 6 weeks if 
treated
IOP < 21 mmHg 21< IOP < 25 mmHg IOP > 25 mmHg
First visit 2–7 days after 
implantation
IOP Visit: 
1 and 2 or 3 months visits then 
every 3 months
NORMAL FOLLOW-UP
Perform imaging + Visual Field
NO TREATMENT REQUIRED
REVIEW WITHIN 6 WEEKS
then normal follow-up or 
according to local practices
IOP > 25 mmHg on 2 active 
medications
If suspected change in visual field, optic disc or retinal nerve fiber layer
Repeat imaging at 6 months, 
then annually if stable
Re-evaluate need for treatment 
at clinician's discretion
Recommend repeat imaging 
and visual fields at 3 months, 
then every 6 months if stable. 
Share results with a glaucoma 
specialist
IOP > 25 mmHg
Fig. 2 Algorithm for the management of IOP elevation by retinal specialists: Post-injection IOP management. IOP
intraocular pressure
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corticosteroid treatment, measurement of IOP
alone is sufficient, without the need for
supplementary examinations. For patients
with OHT (IOP[21 mmHg), or patients
already receiving IOP-lowering medications or
with a history of OHT after corticosteroid
treatment, baseline imaging (such as optical
coherence tomography of optic nerve head and/
or retinal nerve fibre layer) and visual field
testing should be performed for future
reference.
The second algorithm concerns monitoring
and management (Fig. 2). For patients with IOP
B21 mmHg, the standard follow-up protocol
applies. If a patient develops
21\IOP B 25 mmHg, the next visit should be
within 6 weeks; if the IOP remains in this
window, then the standard follow-up protocol
applies. If not previously done, the patient
should have baseline imaging and visual field
testing. For patients developing an IOP
[25 mmHg, treatment should be considered
with IOP-lowering medication or laser
trabeculoplasty according to local practices. If
IOP remains C25 mmHg on two active
medications, then the patient should be
referred to a glaucoma specialist. Overall, the
management of IOP rise in DME patients who
received intravitreal corticosteroid is not
different to other patients with primary OHT
since there is no evidence for an additional risk
for diabetic patients. The panel agreed there is
no need for specific management of IOP
elevation induced by steroids compared with
other causes of IOP rise. Moreover, transitory
OHT per se should not be considered a problem
as long as the risk of conversion to glaucoma is
reduced. Anecdotal experience in treating
steroid-induced OHT suggests that laser
trabeculoplasty is an effective treatment.
In a meta-analysis of randomized controlled
trials, the most efficient IOP-lowering drugs
were prostaglandins followed by non-selective
beta-blockers, alpha-adrenergic agonists,
selective beta-blockers and topical carbonic
anhydrase inhibitors [60]. However, the panel
considered that there were neither particular
preferences nor exclusions of specific classes of
medical treatment in DME patients with
corticosteroid-induced OHT; treatment should
start with monotherapy, as set out in the EGS
guidelines [5]. The use of prostaglandin
analogues is not contraindicated but treating
clinicians need to be aware of the uncommon
occurrence of macular edema from
prostaglandin analogue use [61].
Contraindications particular to each class of
topical anti-glaucoma drugs should be
considered on a case-by-case basis [5].
CONCLUSION
In diabetic patients having intravitreal steroids,
clinical studies indicated that the rates of
elevated IOP and OHT were comparable with
those of non-diabetic patients (for example
patients with uveitis). The panel agreed that
there is no need for specific management
protocol for IOP elevation induced by steroids
compared with other causes of raised IOP.
When necessary, IOP-lowering medical
treatment or laser trabeculoplasty is sufficient
for a large majority of patients and glaucoma
surgery is needed for only a small proportion of
patients.
These principles have been implemented in
an algorithm that is intended to be simple and
practical to provide guiding principles to
ophthalmologists in the management of
corticosteroid-induced IOP elevation.
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